CHRNB4 (Cholinergic Receptor Nicotinic Beta Subunit 4) encodes the β4 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel crucial for cholinergic neurotransmission. The CHRNB4 protein forms part of pentameric neuronal nAChRs that mediate fast synaptic transmission in the central and peripheral nervous systems.
| Property |
Value |
| Symbol |
CHRNB4 |
| Gene Name |
Cholinergic Receptor Nicotinic Beta Subunit 4 |
| Chromosomal Location |
15q25.1 |
| Gene ID |
1143 |
| Category |
Ion Channel / Receptor |
| Protein Family |
Cys-loop receptor family |
¶ Protein Structure and Function
The CHRNB4 protein is a 498-amino acid transmembrane subunit that assembles with other α and β subunits to form functional nAChR channels. The β4 subunit preferentially assembles with α3, α5, and α7 subunits to form receptors with distinct pharmacological and physiological properties.
CHRNB4 is predominantly expressed in:
- Peripheral nervous system: Autonomic ganglia, adrenal medulla
- Brain regions: Hippocampus, cortex, thalamus, basal ganglia
- Neuroendocrine cells: Chromaffin cells, pineal gland
The β4-containing nAChRs typically form:
- α3β4 (predominant in autonomic ganglia)
- α3β4α5 (major brain isoform)
- α4β4 (minor population)
These receptors exhibit distinct pharmacological profiles compared to α4β2 and α7 homomeric receptors, with higher sensitivity to certain agonists and different desensitization kinetics.
CHRNB4 and other nAChR subunits have been implicated in Alzheimer's disease pathophysiology:
- Cholinergic hypothesis: Loss of cholinergic neurons is a hallmark of AD, and nAChRs are critical targets for therapeutic intervention
- Neuroprotection: α4β2 and α7 nAChRs on neurons are neuroprotective against β-amyloid toxicity
- Cognitive function: Nicotinic receptors are involved in attention, learning, and memory
- Therapeutic targeting: Nicotinic agonists have been explored as AD treatments
- Dopaminergic neuron survival: nAChRs modulate dopamine release and may protect dopaminergic neurons
- Levodopa-induced dyskinesias: Nicotinic receptor agonists may reduce dyskinesias in PD patients
- Smoking paradox: The inverse relationship between smoking and PD may involve nicotinic receptors
- Motor neuron function: nAChRs are expressed on motor neurons and may be involved in ALS pathogenesis
- Neuroinflammation: Cholinergic signaling modulates neuroinflammation through α7 nAChR-dependent pathways
Several nicotinic agonists have been investigated for neurodegenerative diseases:
| Compound |
Target |
Development Stage |
Notes |
| ABBV-9E1-2 |
α4β2 |
Preclinical |
PET tracer for α4β2 imaging |
| AZD0328 |
α7 |
Research |
Cognitive enhancement |
| BMS-933043 |
α7 |
Research |
Agonist for AD |
CHRNB4 mutations have been associated with epilepsy syndromes:
- Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
- Generalized epilepsy with febrile seizures plus (GEFS+)
- Nicotine addiction: β4-containing receptors in the habenula-interpeduncular tract are involved in nicotine aversion
- Genetic variants: CHRNB4 polymorphisms affect nicotine dependence risk
- Small cell lung carcinoma: CHRNB4 is frequently overexpressed in SCLC
- Prognostic marker: High CHRNB4 expression correlates with poor prognosis in certain cancers
- nAChR agonists: Selective agonists for α4β2 and α7 receptors
- Positive allosteric modulators (PAMs): Enhance receptor function
- Antagonists: Block receptor overactivation
- Cognitive enhancement: α7 nAChR agonists for AD-related cognitive decline
- Neuroprotection: Nicotinic modulation to prevent neuronal death
- Pain management: nAChR agonists for neuropathic pain
Key research areas include:
- Developing subunit-selective nicotinic agonists
- Understanding nAChR assembly and trafficking
- Identifying disease-specific receptor compositions
- Elucidating the role of nicotinic signaling in neuroinflammation